Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quantum Biopharma ( (TSE:QNTM) ) has issued an announcement.
On August 11, 2025, Quantum BioPharma announced an agreement with a contract development and manufacturing organization to produce an oral formulation of its drug Lucid-MS for a Phase 2 clinical trial targeting multiple sclerosis. This development is a significant step in advancing Lucid-MS, a non-immunomodulatory, neuroprotective compound, as it prepares for an Investigational New Drug application with the FDA. The trial aims to test the drug’s efficacy in helping MS patients regain mobility, potentially strengthening Quantum BioPharma’s position in the neurodegenerative disorder treatment market.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is actively involved in research and development through its subsidiary, Lucid Psycheceuticals Inc., with its lead compound Lucid-MS aimed at treating multiple sclerosis by preventing and reversing myelin degradation.
YTD Price Performance: 581.20%
Average Trading Volume: 7,242
Technical Sentiment Signal: Buy
Current Market Cap: C$115.9M
See more data about QNTM stock on TipRanks’ Stock Analysis page.